Loading…
← CockpitCompetitor Analysis › 603858.SS Shandong Buchang Pharmaceuticals Co., Ltd. Class AOpen in the cockpit ↗

Shandong Buchang Pharmaceuticals Co., Ltd. Class A603858.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese TCM pharma company known for Naoxintong and other cerebro/cardiovascular traditional-medicine products.

Momentum leader 82
Mkt cap
$2.25B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$12.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+3.8 pp
WACC 5.6%
Hurdle
+3 pp
Req g minus delivered
Close · CNYCN¥14.68
1D-0.7%
1W-1.1%
1M-0.1%
3M-8.2%
6M-7.2%
YTD-6.1%
1Y-14.6%
ATR %2.1%
52w lowhigh20.5% off high

What Shandong Buchang Pharmaceuticals does

Chinese TCM pharma company known for Naoxintong and other cerebro/cardiovascular traditional-medicine products.

Relies on a single brand franchise, Naoxintong, sold through hospitals and drugstores under national reimbursement listing. It markets heavily to doctors and pharmacy chains, so selling expenses are the main cost. Founder-controlled.

Products and services

  • Naoxintong capsules
  • Other TCM cardiovascular products

Customers

  • Hospitals/pharmacies treating cardiovascular/strok

Where it sits in the supply chain

  • Health Care
  • Traditional Chinese medicine
  • TCM cerebro/cardiovascular products

What could go right

  • Aging-population cardiovascular/stroke treatment demand

What could go wrong

  • TCM efficacy/regulatory scrutiny
  • Centralized procurement price pressure

Moat: narrow (brand). Well-known branded TCM formula for stroke/cardiovascular care with established physician trust.

Headquarters: Shandong, China · Employees: 7,237

Named competitors

Shandong Buchang Pharmaceuticals at a glance

Size Shandong Buchang Pharmaceuticals (603858.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.25B, the 1068th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.68 on 18 Nov 2026.

Performance Over six months the shares fell 7.2%, against -5.0% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 4.2% over the last twelve months (peer median +5.1%); the operating margin is 9.8% (peer median 13.9%).

Valuation It trades at 1.5× enterprise value to sales against a peer median of 3.8× (2nd cheapest of 20).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.8 points above its cost of capital (5.6% WACC).

Relative performance

909510010521 May 202621 Aug 202618 Nov 2026Peer median 97603858.SS 94
Six months, rebased to 100: Shandong Buchang Pharmaceuticals against the median of its 20 peers (local-currency closes).

Shandong Buchang Pharmaceuticals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥11.4BCN¥11.8BCN¥10.9BCN¥13.1BCN¥14.8B
Revenue growth—+8%-17%-11%—
Gross profitCN¥7.25BCN¥7.21BCN¥6.17BCN¥8.57BCN¥10.2B
EBITDAn/aCN¥1.69BCN¥1.30BCN¥1.65BCN¥2.30B
Net incomeCN¥282MCN¥361M-CN¥554MCN¥319M-CN¥1.53B
Free cash flowCN¥784MCN¥1.05BCN¥753M-CN¥694MCN¥2.24B
Capital expenditureCN¥196MCN¥123MCN¥197MCN¥530MCN¥543M
Total debtCN¥4.11BCN¥3.86BCN¥3.76BCN¥3.41BCN¥3.39B

Quarterly statements and history in the cockpit →

Shandong Buchang Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%APLLTD600867600267301080RGCPRGO000250NAMS001321623696PBH214450H02688428ALM600285603707301301603456603858.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shandong Buchang Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×20×40×60×APLLTD600867600267301080PRGO000250NAMS21623696H02688428301301603858.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shandong Buchang Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%APLLTD600867600267301080PRGO214450688428603858.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shandong Buchang Pharmaceuticals is the large dot.

Shandong Buchang Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (603858.SS vs 600535.SS vs 002603.SZ vs 600557.SS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Shandong Buchang Pharmaceuticals 603858.SS$2.25B-7%+4%10%1.5×-2.5%
Tasly Pharmaceutical 600535.SS$3.19B-2%-4%19%2.2×-7.5%
Shijiazhuang Yiling Pharmaceutical 002603.SZ$3.83B-7%+32%21%2.9×-3.9%
Jiangsu Kanion Pharmaceutical 600557.SS$989M-9%+8%7%1.4×2.3%

How Shandong Buchang Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shandong Buchang Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure603858.SSPeer medianRank in peer set
1-month return-0.1%-5.5%6th highest of 21
6-month return-7.2%-5.0%11th highest of 21
Distance from 52-week high-20.5%-29.6%7th highest of 21
Revenue growth (TTM)+4.2%+5.1%9th lowest of 20
Operating margin9.8%13.9%8th lowest of 19
EV / Sales1.5×3.8×2nd cheapest of 20
Growth the price implies (Req g, 7 yrs)-2.5%3.3%5th least demanding of 17
Growth delivered (Del g)-5.8%+8.5%lowest of 17
Hurdle (Req g minus delivered)+3.3 pp-0.9 pp6th most demanding of 17
ROIC minus cost of capital+3.8 pp-0.4 pp5th highest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%1.5×-2.5%-5.8%
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%2.6×26.7%+6.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a4.2×0.9%+0.3%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%1.7×-9.7%-1.5%
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%14.0×41.3%+27.7%
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
Perrigo PRGOUnited States$2.35B+52%-4%5%1.3×14.1%+0.8%
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%11.8×n/an/a
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%67.0×n/an/a
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%2.0×47.0%+19.3%
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%16.8×n/an/a
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%13.6×37.9%+22.9%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%3.8×2.3%+2.9%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%4.0×-11.0%+37.6%
Haw Par H02.SISingapore$2.08B-25%-13%30%8.4×3.2%+15.7%
InnoCare Pharma 688428.SSChina$2.07B-7%+135%35%2.8×-10.9%+344.2%
Almirall ALM.MCSpain$2.46B-13%+24%8%1.9×6.1%+6.5%
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%3.3×-4.7%+10.6%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%3.2×5.1%+6.4%
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%4.2×3.4%+4.8%
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%2.4×1.7%+15.7%

Questions

Who are Shandong Buchang Pharmaceuticals's main competitors?
Named competitors: Tasly Pharmaceutical Group (600535.SS), Yiling Pharmaceutical (002603.SZ), Jiangsu Kanion Pharmaceutical (600557.SS). The cockpit's measured peer set (industry) also includes Alembic Pharmaceuticals (APLLTD.NS), Tonghua Dongbao Pharmaceutical (600867.SS), Zhejiang Hisun Pharmaceutical (600267.SS), Acrobiosystems (301080.SZ), Regencell Bioscience (RGC), Perrigo (PRGO).
Is Shandong Buchang Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 1.5× against a peer median of 3.8×, 2nd cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Shandong Buchang Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -7.2% against -5.0% for the median peer; over one year -14.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.